Cytoxan Related Clinical Trials
Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394) [Active, not recruiting]
High-Dose Intravenous (IV) Cyclophosphamide Versus Monthly IV Cyclophosphamide [Active, not recruiting]
Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer [Active, not recruiting]
A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing [Active, not recruiting]
A Three Arm Study of Adriamycin, Cyclophosphamide Plus Docetaxel vs Adriamycin Plus Cyclophosphamide Followed By Paclitaxel vs Adriamycin Plus Cyclophosphamide Followed By Paclitaxel and Gemcitabine in Adjuvant Breast Cancer [Active, not recruiting]
Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan [Active, not recruiting]
Scleroderma Cyclophosphamide or Transplantation (SCOT) Study [Recruiting]
Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients [Active, not recruiting]
Docetaxel in Breast Cancer [Active, not recruiting]
Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer [Active, not recruiting]
Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12 [Active, not recruiting]
Docetaxel in Combination With Doxorubicin and Cyclophosphamide (TAC) Versus 5-Fluorouracil in Combination With Doxorubicin and Cyclophosphamide (5 FAC) as Adjuvant Treatment of Breast Cancer Patients [Completed]
Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides [Completed]
Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility [Active, not recruiting]
Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia [Active, not recruiting]
Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors [Recruiting]
Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer [Active, not recruiting]
Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer [Recruiting]
Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients [Recruiting]
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer [Terminated]
A Pharmacokinetic and Phase II Study of Oral Cyclophosphamide and Topotecan in Children With Recurrent Solid Tumors [Recruiting]
Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis [Not yet recruiting]
Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab [Active, not recruiting]
Phase II Fludarabine, Cytoxan and FCCAM in Untreated B-Cell Chronic Lymphocytic Leukemia [Recruiting]
A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer [Completed]
Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma [Completed]
Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients [Recruiting]
Neoadjuvant Treatment of Breast Cancer [Active, not recruiting]
Five-Year Actively Controlled Clinical Trial in New Onset Juvenile Systemic Lupus Erythematosus Nephritis [Withdrawn]
BIG 02/98 Docetaxel - Breast Cancer [Active, not recruiting]
Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) [Recruiting]
Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis [Recruiting]
Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer [Completed]
Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer [Recruiting]
High-Dose Total-Body Irradiation, Cyclophosphamide, Antithymocyte Globulin, and Autologous Stem Cell Transplant or High-Dose Cyclophosphamide in Treating Patients With Severe Systemic Sclerosis [Recruiting]
Cyclophosphamide Drug Interaction Study In Cancer Patients [Recruiting]
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Immunodeficiency or Noncancerous Inherited Disorders [Recruiting]
Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma [Recruiting]
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. [Recruiting]
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer [Recruiting]
Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens [Recruiting]
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma [Recruiting]
Cyclophosphamide and Donor Lymphocytes in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders [Recruiting]
Cyclophosphamide, Cellular Adoptive Immunotherapy, and Aldesleukin in Treating Patients With Metastatic Melanoma [Recruiting]
Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With MM [Recruiting]
Vaccine Therapy, Interferon Alfa, and Cyclophosphamide in Treating Patients With Stage IV Breast Cancer [Recruiting]
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer [Completed]
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma [Suspended]
Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia [Active, not recruiting]
Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer [Recruiting]
Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia [Active, not recruiting]
Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement [Recruiting]
Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia [Active, not recruiting]
Phase II Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer [Recruiting]
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma [Recruiting]
Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation [Recruiting]
Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer [Completed]
Pentostatin and Rituximab With or Without Cyclophosphamide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia [Active, not recruiting]
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma [Recruiting]
Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia [Recruiting]
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma [Recruiting]
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma [Recruiting]
Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma
Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer [Not yet recruiting]
A Cancer Vaccine (CG8123) Given With and Without Cyclophosphamide for Advanced Stage Non-Small Cell Lung Cancer (NSCLC) [No longer recruiting]
Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia [Recruiting]
Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer [Recruiting]
Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients [Recruiting]
Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer [Recruiting]
High Dose Cyclophosphamide for Treatment of Scleroderma [Recruiting]
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies [Recruiting]
Study of Dose-Dense Adriamycin Plus Cytoxan (AC) Followed by Either Abraxane or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer [Active, not recruiting]
Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy [Recruiting]
Imatinib Mesylate, Bevacizumab, and Cyclophosphamide in Treating Patients With Refractory Metastatic Solid Tumors [Recruiting]
Cyclophosphamide and Busulfan Followed By Donor Stem Cell Transplant in Treating Patients With Myelofibrosis [Recruiting]
Cyclophosphamide and Filgrastim Followed By Stem Cell Transplant in Treating Patients With Chronic or Accelerated Phase Myelogenous Leukemia [Recruiting]
Cyclophosphamide in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Fanconi's Anemia [Recruiting]
Liposomal Doxorubicin and Cyclophosphamide in Treating Women With Stage IV Breast Cancer [Recruiting]
Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia
Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL) [Recruiting]
Cyclophosphamide, Fludarabine, and Donor White Blood Cells in Treating Patients With Hematologic Cancer That Relapsed After a Previous Donor Stem Cell Transplant [Recruiting]
Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer (With Trastuzumab in HER2 + Patients) [Recruiting]
Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer [Recruiting]
Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma [No longer recruiting]
Phase II High-Dose Cyclophosphamide for Multiple Sclerosis [Recruiting]
Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders [Recruiting]
Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin's Lymphoma [Recruiting]
Cyclophosphamide and Antithymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing a Donor Bone Marrow Transplant [Recruiting]
Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer [No longer recruiting]
Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer [Active, not recruiting]
Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer [No longer recruiting]
Karenitecin in Pediatric Patients With Refractory or Recurrent Solid Tumors N10010) [Recruiting]
Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer [Recruiting]
Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin [Recruiting]
Paclitaxel/Cyclophosphamide and High-Dose Melphalan/Etoposide Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage IIIB Inflammatory Breast Cancer [Recruiting]
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing an Umbilical Cord Blood Transplant for Hematologic Cancer [Recruiting]
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Treating Young Patients With Relapsed or Progressive Cancer [Recruiting]
ABT-888 and Cyclophosphamide in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma [Recruiting]
Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases [Recruiting]
Fludarabine, Cyclophosphamide, and Rituximab (FCR) Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia [Recruiting]
Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma [Recruiting]
|
